Biogen/CV Therapeutics CVT-124 target market will be diuretic-resistant hospitalized CHF patients.
Executive Summary
BIOGEN/CV THERAPEUTICS CVT-124 DEVELOPMENT WILL TARGET DIURETIC- RESISTANT hospitalized congestive heart failure patients, CV Therapeutics said in a recent public offering prospectus. The company estimates that one-quarter of the 875,000 patients hospitalized annually with a primary diagnosis of CHF exhibit resistance to diuretic treatments "due to excessive fluid reabsorption in the proximal tubule." CVT-124, the prospectus states, blocks "the adenosine A1 receptors in the proximal tubule that would ordinarily stimulate sodium reabsorption at that site."